Evidence map›Paper›PMID 21416157›Full record

ArticleMedical oncology (Northwood, London, England)2012

Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer.

Yu Tang, Xiangtian Zeng, Fei He, Yonghui Liao, Niansong Qian, Masakazu Toi

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Yu TangDepartment of Ultrasound, PLA 302 Hospital, Beijing, China.
Xiangtian Zeng
Fei He
Yonghui Liao
Niansong Qian
Masakazu Toi
Air Force Medical University · CNKyoto University · JPPLA 306 Hospital · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Caveolin-1 is the principal components of caveolae membranes, implicated in oncogenesis and angiogenesis. Until now, its expression and functional significance in hepatocellular carcinoma (HCC) are still unclear. In the present study, we demonstrated that expression of caveolin-1 was markedly upregulated in HCC patients. In addition, increased caveolin-1 expression correlated positively with the histological differentiation, portal venous invasion, hepatic venous invasion, intrahepatic metastases, and recurrence, suggesting a role for caveolin-1 in the progression of HCC. HepG2 cell line was transfected with pcDNA3.1/caveolin-1 to observe the significance of the change in caveolin-1 expression. We showed that caveolin-1 overexpression could not only protect HepG2 cells from apoptosis but also enhance its migration and invasion by upregulating MMP-2, MMP-9, and VEGF expressions. Collectively, our clinical and in vitro data indicate that the status of caveolin-1 expression may be one of causative factors for the invasion and poor prognosis in HCC.

Indexed as

ApoptosisCell MovementBlotting, WesternCarcinoma, HepatocellularCaveolin 1Cell AdhesionCell ProliferationDisease ProgressionFemaleHumansImmunoenzyme TechniquesLiver NeoplasmsMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingCaveolin 1

Identifiers

PMID21416157
OpenAlexW2045802076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.